PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.79%
Both companies show declining cash positions (-13.79% vs TRVN's -17.75%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-13.79%
Cash + STI yoy 0.75-0.9x TRVN's -17.75%. Bill Ackman would wonder if competitor is building liquidity more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x TRVN's -23.50%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-99.57%
≥ 1.5x TRVN's -18.28%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-99.57%
≥ 1.5x TRVN's -16.37%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
12.57%
Less than half of TRVN's -18.90%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.70%
Less than half of TRVN's 16.90%. David Dodd sees a more disciplined short-term liability approach.
-28.84%
Less than half of TRVN's -100.00%. David Dodd sees more deleveraging vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.84%
Above 1.5x TRVN's -0.77%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-22.64%
Less than half of TRVN's 1.42%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.84%
≥ 1.5x TRVN's -0.82%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.67%
0.5-0.75x TRVN's -22.96%. Martin Whitman is wary of lagging equity growth vs. competitor.
-99.57%
≥ 1.5x TRVN's -16.37%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-28.84%
Less than half of TRVN's -94.51%. David Dodd sees less overall debt expansion vs. competitor.
-28.87%
Less than half of TRVN's -156.99%. David Dodd sees better deleveraging or stronger cash buildup than competitor.